



PTO/SB/21 (09-04)

 Approved for use through 07/31/2006. OMB 0651-0031
 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

		Application Number	10/051,652
		Filing Date	January 15, 2002
		First Named Inventor	Manuel L. Penichet
		Group Art Unit	1643
		Examiner Name	Hon Sang
Total Number of Pages in This Submission		Attorney Docket Number	407J-001700US

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	<input type="checkbox"/> PTO-1449 form, cited references, Statement under 37 CFR 1.97(d)-(e)(1), copy of EP Search Report and receipt acknowledgment postcard
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Small Entity Statement	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		
Authorization to Charge Deposit Account Please charge Deposit Account No. 50-0893 for any additional fees associated with this paper or during the pendency of this application, including any extensions of time for consideration of the documents enclosed.		
Remarks <div style="border: 1px solid black; height: 40px; width: 100%;"></div>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Paul Littlepage, Reg. No. 48,581, Quine Intellectual Property Law Group, P.C.
Signature	
Date	June 30, 2006

CERTIFICATE OF MAILING


I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

Typed or printed name	Evelyn Gomez	
Signature		Date
	June 30, 2006	



I hereby certify that this correspondence is
being deposited with the United States
Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450
Alexandria, VA 22313-1450,
On June 30, 2006

Quine Intellectual Property Law Group, P.C.

By 
Evelyn Gomez

Attorney Docket No. 407J-001700US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:
Manuel L. Penichet, *et al.*

Application No.: 10/051,652
Filed: January 15, 2002

For: ANTIBODY-AVIDIN FUSION
PROTEINS AS CYTOTOXIC DRUGS

Examiner: Hon Sang

Art Unit: 1643

Statement under 37 C.F.R. §1.97(d)-(e)(1)


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

CERTIFICATION

I hereby certify that each item of information contained in the information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

Respectfully submitted,


Paul Littlepage, Reg. No. 48,581

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.
P.O. Box 458
Alameda, CA 94501
Tel: (510) 337-7871 / Fax: (510) 337-7877



I hereby certify that this correspondence is being deposited with the United States Postal Service first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450,
Alexandria, VA 22313-1450, on June 30, 2006

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.

By

Evelyn Gomez

Attorney Docket No. 407J-001700US
Client Ref. No. 2002-100-1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Manuel L. Penichet, et al.

Application No.: 10/051,652

Filed: January 15, 2002

For: ANTIBODY-AVIDIN FUSION
PROTEINS AS CYTOTOXIC DRUGS

Examiner: Hon Sang

Art Unit: 1643

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR § 1.97 and
§ 1.98

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450


Sir:

The references cited on attached form PTO-1449 are being called to the attention of the Examiner. Copies of the references are enclosed. Also, enclosed is a copy of European Search Report for corresponding European Application No. 03710672.1. It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

This IDS is being filed after the mailing date of the Final Office Action, but within 3 months of the information first being cited in a communication from a foreign patent office for a counterpart foreign application. Please deduct \$180.00, pursuant to 37 CFR §1.17(p), from the undersigned's Deposit Account No. 50-0893. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,


Paul Littlepage
Reg. No. 48,581

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.
P.O. BOX 458
Alameda, CA 94501
(510) 337-7871
Fax (510) 337-7877

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/051,652		
(use as many sheets as necessary)		Filing Date	January 15, 2002		
		First Named Inventor	Manuel L. Penichet		
		Group Art Unit	1643		
		Examiner Name	Hon Sang		
		Attorney Docket Number	407J-001700US		
		Date Submitted	June 30, 2006		

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS							
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					T
	1	GHETIE et al. "Homodimerization of tumor-reactive Monoclonal Antibodies Markedly Increases their Ability to Induce Growth Arrest or Apoptosis of Tumor Cells", Proc. Natl. Acad. Sci. USA, Vol. 94, pp. 7509-7514, (1997).					
	2	GREEN, "Avidin and Streptavidin", Methods in Enzymology, Academic Press, Inc. Vol. 184, pp. 51-67, (1990).					
	3	LESLEY et al., "Inhibition of Cell Growth by Monoclonal Anti-Transferrin Receptor Antibodies", Mol. and Cell. Biology, Vol. 8, pp. 1814-1821, (1985).					
	4	LITTLE et al., "Of mice and men: Hybridoma and Recombinant Antibodies", Immunology Today, Vol. 21, No. 8, pp. 364-370, (2000).					
	5	KEMP et al., "Effects of Anti-Transferrin Receptor Antibodies on the Growth of Neoplastic Cells", Pathobiology, Vol. 60, No. 1, pp. 27-32, (1992).					
	6	KIPRIYANOV et al., "Affinity Enhancement of a Recombinant Antibody: Formation of complexes with Multiple Valency by a Single-Chain Fv Fragment-core Streptavidin Fusion", Protein Engineering, Vol. 9, No. 2, pp. 203-211, (1996).					
	7	TAETLE et al., "Mechanisms of Growth Inhibition by Anti-Transferrin Receptor Monoclonal Antibodies", Cancer Research, Vol. 46, No. 4, pp. 1759-1763, (1986).					
	8	STONE et al., "A Tetravalent Single Chain Antibody-Streptavidin Fusion Protein Induces Apoptosis in Human B-Lymphoma Cells", Proceeding of the Amer. Assoc. for Cancer Research Annual Meeting, Vol. 43, page 881, (2002).					
	9	WOLFF et al., Monoclonal Antibody Homodimers: Enhanced Antitumor Activity in Nude Mice", Cancer Research, Vol. 53, No. 11, pp. 2560-2565, (1993).					

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.